• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Humanigen Inc.

    8/14/23 4:05:10 PM ET
    $HGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HGEN alert in real time by email
    NT 10-Q 1 z811230nt10q.htm

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

      FORM 12b-25

    NOTIFICATION OF LATE FILING
    SEC FILE NUMBER

    001-35798

     

    (Check one):    ☐ Form 10-K    ☐ Form 20-F    ☐ Form 11-K    ☒ Form 10-Q    ☐ Form 10-D    ☐ Form N-SAR   ☐ Form N-CSR

     

      For Period Ended: June 30, 2023

     

      ☐  Transition Report on Form 10-K
       
      ☐  Transition Report on Form 20-F
       
      ☐  Transition Report on Form 11-K
       
      ☐  Transition Report on Form 10-Q
       
      ☐  Transition Report on Form N-SAR

     

      For the Transition Period Ended:

     

     

    Read Instructions (on back page) Before Preparing Form.  Please Print or Type.
    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:  N/A
     

     

    PART I — REGISTRANT INFORMATION

     

    Humanigen, Inc.
    Full Name of Registrant
     
    Former Name if Applicable
     
    830 Morris Turnpike, 4th Floor
    Address of Principal Executive Office (Street and Number)
     
    Short Hills, NJ 07078
    City, State and Zip Code

     

     

       
     

     

    PART II — RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.  (Check box if appropriate)

     

    x (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
         
    ¨ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
         
    ¨ (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III — NARRATIVE

     

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.  (Attach extra Sheets if Needed.)

     

    As previously reported in its Current Report on Form 8-K filed on July 25, 2023, the Company has been unsuccessful in its attempts to identify and complete a strategic transaction in the first half of 2023 or in raising debt or equity financing in sufficient amounts and with acceptable terms to fund the Company’s operations going forward.

     

    In light of the above, and the Company’s limited cash and cash equivalents, the Company anticipates that it will not be able to continue as a going concern and is exploring all restructuring options, which may include commencing a bankruptcy or other insolvency proceeding in the third quarter of 2023. The Company is continuing to evaluate term sheets relating to potential sales of assets in a bankruptcy proceeding. Given the Company’s lack of liquidity, any such bankruptcy filing may result in a complete or substantial loss of value for holders of our common stock.

     

    Due to the Company’s focus on resolving its financial situation, the Company has been unable to focus its attention on preparing its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023 (the “Report”) and thus is unable to file the Report by the prescribed due date of August 14, 2023 without unreasonable effort or expense. As a result, the Company and its independent auditor need additional time to complete certain disclosures and analyses required to be included in the Report.  

     

    PART IV — OTHER INFORMATION

     

    (1)Name and telephone number of person to contact in regard to this notification

     

    Cameron Durrant   (973)   200-3010
    (Name)   (Area Code)   (Telephone Number)

     

    (2)Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed?  If the answer is no, identify report(s).

     

    Yes ☒       No ☐

     

    (3)Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     

    Yes ☒       No ☐

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    There will likely be significant changes in the Company's operating expenses for the three months ended June 30, 2023 as compared to the three months ended June 30, 2022 and for the six months ended June 30, 2023 as compared to the six months ended June 30, 2022. A reasonable estimate of such changes cannot be made at this time because the financial statements are still being compiled.

     
     
    HUMANIGEN, INC.
    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: August 14, 2023   By: /s/  Cameron Durrant
          Name: Cameron Durrant
          Title: Chairman of the Board and Chief Executive Officer

     

     

     

     

     

    Get the next $HGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HGEN

    DatePrice TargetRatingAnalyst
    7/13/2022$13.00 → $2.00Buy → Neutral
    ROTH Capital
    7/13/2022$30.00 → $2.00Overweight → Neutral
    Cantor Fitzgerald
    7/13/2022Buy → Neutral
    H.C. Wainwright
    9/10/2021$9.00Buy → Hold
    Jefferies
    9/9/2021Outperform → Neutral
    Credit Suisse
    9/9/2021$36.00 → $28.00Buy
    H.C. Wainwright
    9/9/2021Neutral → Underweight
    JP Morgan
    8/13/2021$25.00 → $24.00Outperform
    Credit Suisse
    More analyst ratings

    $HGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Humanigen Inc. (Amendment)

      SC 13G/A - HUMANIGEN, INC (0001293310) (Subject)

      2/1/23 1:21:00 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Humanigen Inc. (Amendment)

      SC 13D/A - HUMANIGEN, INC (0001293310) (Subject)

      3/17/22 4:28:37 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Humanigen Inc. (Amendment)

      SC 13G/A - HUMANIGEN, INC (0001293310) (Subject)

      2/14/22 4:54:04 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    SEC Filings

    See more
    • Humanigen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - HUMANIGEN, INC (0001293310) (Filer)

      1/8/24 5:02:09 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Humanigen Inc.

      25-NSE - HUMANIGEN, INC (0001293310) (Subject)

      10/12/23 8:19:55 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - HUMANIGEN, INC (0001293310) (Filer)

      9/14/23 4:01:46 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia

      CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosisEleven subjects dosed with lenzilumab and with current standard of care, azacitidineSix evaluable subjects, including those with high risk CMML, demonstrated clinical benefit at three months follow-upLenzilumab appears to be well-toleratedShort Hills, New Jersey and Adelaide, South Australia--(Newsfile Corp. - April 14, 2023) - Humanigen, Inc. (NASDAQ:HGEN), Humanigen Australia Pty Ltd, (Humanigen) and the South Australian Health and Medical Research Institute (SAHMRI) today presented (poster CT085/13); the design and baseline results of the Precision Approach to Chronic Myelomono

      4/14/23 12:05:00 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen Reports Third Quarter 2022 Financial Results

      Short Hills, New Jersey--(Newsfile Corp. - November 14, 2022) - Humanigen, Inc. (NASDAQ:HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the third quarter and nine months ended September 30, 2022.In July 2022, the company announced a strategic realignment of its pipeline, resources and regulatory strategy. The company is accelerating the development of lenzilumab in chronic myelomonocytic leukemia (CMML), a rare blood cancer, for which the PREACH-M study is already underway. The company is also contin

      11/14/22 4:01:00 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference

      Short Hills, New Jersey--(Newsfile Corp. - November 10, 2022) - Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions, today announced that Cameron Durrant, MD, MBA, Chairman & CEO, will give a corporate presentation at 11:25am EST (4:25pm local time) at the Jefferies London Healthcare Conference taking place on November 17, 2022. Dr. Durrant will provide an update on the clinical development of lenzilumab, Ifabotuzumab and HGEN005.A livestream will be available and a webcast link to a recording of the event will be posted to the "Events and Presentations" section of Humanige

      11/10/22 8:02:00 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors

      Former Novartis Veteran Brings Deep Expertise in Drug Development and Commercialization CAMBRIDGE, Mass., Sept. 1, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to using mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced the appointment of Rainer Boehm as an independent director to its Board of Directors. Mr. Boehm will serve on Omega's audit and compensation committees. "Rainer's growth-oriented perspective and global strategic management experience will be invaluable to Omega in this next phase o

      9/1/22 7:00:00 AM ET
      $CLLS
      $HGEN
      $OMGA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space

      Appoints Timothy E. Morris, a veteran biotech executive with over 35 years of experience in executive and financial leadership, to Board of DirectorsNames Kenneth Truitt, M.D., with over 25 years of clinical and regulatory experience across biotechnology and large pharmaceutical companies, as Chief Medical Officer Reports inducement grant to Dr. Truitt under Nasdaq Listing Rule 5635(c)(4) WARREN, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today the appointments of Timothy E. Mo

      8/10/22 4:50:35 PM ET
      $AQST
      $DBVT
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Humanigen Announces Ken Trbovich Appointed as Senior Vice President, Investor Relations

      BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced the appointment of Ken Trbovich to the newly-created role of SVP of Investor Relations, effective immediately, reporting to Timothy E. Morris, COO/CFO of Humanigen. Mr. Trbovich brings to Humanigen 20 years of experience on Wall Street as a Managing Director and Senior Analyst at several leading investment banks including Janney Montgomery Scott, MLV & Co. (now part of B. Riley), C.E. Unterberg, Towbin (now part of C

      6/7/21 8:00:00 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chappell Dale sold $4,250 worth of shares (386,350 units at $0.01) (SEC Form 4)

      4 - HUMANIGEN, INC (0001293310) (Issuer)

      10/20/23 6:50:35 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Hohneker John

      4 - HUMANIGEN, INC (0001293310) (Issuer)

      7/29/22 6:31:06 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Buxton Cheryl

      4 - HUMANIGEN, INC (0001293310) (Issuer)

      7/29/22 6:31:07 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Financials

    Live finance-specific insights

    See more
    • Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update

      Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that it will host a conference call and webcast to discuss The Lancet Respiratory Medicine publications and provide a corporate update at 8am EST on December 2, 2021. The peer-reviewed paper in The Lancet Respiratory Medicine is available via the follow link: https://doi.org/10.1016/S2213-2600(21)00494-X The associated comment in The Lancet Respiratory Medicine is available via the following link: https://doi.org/10.1016/S2213-2600(21)00539-7 Details about how to access the conference call and webcast are pr

      12/1/21 6:45:00 PM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Humanigen downgraded by ROTH Capital with a new price target

      ROTH Capital downgraded Humanigen from Buy to Neutral and set a new price target of $2.00 from $13.00 previously

      7/13/22 9:07:33 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Humanigen from Overweight to Neutral and set a new price target of $2.00 from $30.00 previously

      7/13/22 7:40:18 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Humanigen downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Humanigen from Buy to Neutral

      7/13/22 7:39:46 AM ET
      $HGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care